Hemics starts cost-effectiveness and efficacy HandScan study in rheumatoid arthritis
31 March 2014, Eindhoven, the Netherlands – Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of rheumatoid arthritis (RA). The study will be performed at the University Medical Center (UMC) Utrecht and four general hospitals in the same region, partners of the Stichting Reumaonderzoek Utrecht (SRU), in collaboration with the Dutch Arthritis Foundation and Hemics.
In an earlier study in UMC Utrecht using Ultrasound (US) measurements as gold standard, a prototype of the HandScan showed superior performance in detecting joint inflammation when compared to clinical examination, suggesting that HandScan is a better tool for monitoring RA. The present study will determine whether this is indeed the case.
The study is supported by the Dutch Arthritis Foundation and the Dutch government through an LSH Impulse subsidy. Five HandScan devices will be placed at UMC Utrecht and 4 regional general hospitals within the collaboration of the SRU.